We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Capregen | LSE:CGN | London | Ordinary Share | GB00B1ZBZK91 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.125 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:7387A Tarsus Group PLC 24 July 2007 24 July 2007 Tarsus Group PLC CapRegen plc - Admission to AIM Tarsus Group plc (LSE: TRS) ('Tarsus'), the international media group with interests in exhibitions, conferences, publishing and online media, is delighted to announce that CapRegen plc ('CapRegen') has been admitted to AIM after successfully raising #3.2 million, before expenses, by way of a placing with institutional and other investors at a placing price of 5p per Ordinary Share of 1p each (the 'Placing Price'), valuing the CapRegen's issued ordinary share capital at #4,450,500 on Admission. Following the placing, Tarsus has a beneficial ownership of 15,500,000 Ordinary Shares in CapRegen (worth #775,000 at the Placing Price), representing 17.4% of CapRegen's enlarged issued share capital. CapRegen is a newly incorporated public limited company that has been established in order to make investments in the global anti-ageing and regenerative medicine market place. CapRegen will use the expertise of Dr Robert Goldman, PhD, DO, FAASP and Dr Ronald Klatz., D.O. to invest in medical technologies that they and the other Directors believe have commercial viability. Dealings in CapRegen's shares commenced as of 8.00am today, 24 July 2007 under the ticker symbol CGN. Further information about CapRegen's is available in its announcement released today. Douglas Emslie, Group Managing Director of Tarsus Group plc and Chairman, CapRegen plc said: "CapRegen's IPO is an exciting development for Tarsus and follows the acquisition of MCII which owns and operates the three leading medical sector exhibitions and conferences in the US anti-ageing market. MCII's first major medical event of the year in Orlando was significantly ahead of the prior year with revenues up 112%. "Tarsus now has extensive knowledge of the anti-ageing market and CapRegen brings together specific healthcare and investment expertise to capitalise on opportunities in this fast growing sector. With a number of potential investee companies already available to the company, CapRegen is in an extremely strong position to generate exciting returns for its shareholders." Enquiries: Tarsus Group plc 020 8846 2700 Doug Emslie, Group Managing Director Madano Partnership 020 7593 4000 Mark Way / Matthew Moth IR Focus 020 7593 4000 Neville Harris This information is provided by RNS The company news service from the London Stock Exchange END MSCVZLBLDDBFBBX
1 Year Capregen Chart |
1 Month Capregen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions